Clinical Trial Update: Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A pharmacogenetic study of Sorafenib in Egyptian patients with hepatocellular carcinoma is planned as Phase 1/Phase 2 and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Assiut University | Conditions: HCC, Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING